# HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

> **NCT05322720** · PHASE2 · UNKNOWN · sponsor: **Taizhou EOC Pharma Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** EOC202
- **DRUG:** albumin-bound paclitaxel

## Key facts

- **NCT ID:** NCT05322720
- **Lead sponsor:** Taizhou EOC Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04
- **Primary completion:** 2023-03
- **Final completion:** 2025-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322720, "HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05322720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*